776 abstracts found.



Results filter

DNA repair genes in Sudanese colorectal cancer

Year:

Session type:

Omnia Yousif1, Suleiman Suleiman2, Muntaser Ibrahim1, Omer Elfarog2
1Institute of Endemic Diseases, Khartoum, Sudan, 2Soba University Hospital, Khartoum, Sudan

Ethnic differences in mammographic density and their determinants: A cross-sectional study among Caucasian and Indian women

Year:

Session type:

Constantinos Savva1, Zoe Aitken2, Isabel dos Santos Silva2
1Norfolk and Norwich University Hospital, Norwich, UK, 2London School of Hygiene & Tropical Medicine, London, UK

Evaluation of the NHS Breast Screening Programme: Results from the London pilot study

Year:

Session type:

Nathalie Massat1, Amanda Dibden1, Dharmishta Parmar1
1Queen Mary, University of London, London, UK

Reduction in interval cancer rates following the introduction of two-view mammography in the UK breast screening programme

Year:

Session type:

Amanda Dibden1, Judith Offman1, Dharmishta Parmar1, Jacquie Jenkins2, Jo Slater3, Kathie Binysh4, Joan McSorley5, Suzanne Scorfield6, Pam Cumming7, Xiao-Hui Liao8, Michael Ryan9, Diane Harker10, Guy Stevens11, Nicola Rogers12, Roger Blanks13, Sarah Sellars14, Julietta Patnick14, Stephen Duffy1
1Queen Mary, University of London, London, UK, 2East Midlands Quality Assurance Reference Centre, Nottingham, UK, 3East of England Quality Assurance Reference Centre, Cambridge, UK, 4London Quality Assurance Reference Centre, London, UK, 5Northern Ireland Quality Assurance Reference Centre, Belfast, UK, 6North East, Yorkshire and the Humber Quality Assurance Reference Centre, Newcastle Upon Tyne, UK, 7North West Quality Assurance Reference Centre, Oldham, UK, 8South Central Quality Assurance Reference Centre, Oxford, UK, 9South East Coast Quality Assurance Reference Centre, East Sussex, UK, 10South West Quality Assurance Reference Centre, Bristol, UK, 11Public Health Wales, Cardiff, UK, 12West Midlands Quality Assurance Reference Centre, Birmingham, UK, 13University of Oxford, Oxford, UK, 14NHS Cancer Screening Programmes, Sheffield, UK

Investigation of an epigenetic cancer risk biomarker reveals glucose metabolism as a key determinant of DNA methylation

Year:

Session type:

Kevin Brennan1, Charlotte Wilhelm-Benartzi1, Kirsty Flower1, Karin van Veldhoven1, Silvia Polidoro2, Carlotta Sacerdote2, Alessio Nacarrati2, Paolo Vineis1,2, Robert Brown1,3, James Flanagan1
1Imperial College London, London, UK, 2HuGeF Foundation, Torino, Italy, 3Institute of Cancer Research, London, UK

Obesity and the outcome of young breast cancer patients in the UK: The POSH study

Year:

Session type:

Ellen Copson1, Ramsey Cutress1, Bryony Eccles1, Clarice Wong1, Tom Maishman1, Sue Gerty1, Louise Dent1, Douglas Altman2, Lorraine Durcan1, Peter Simmonds1, the POSH steering group and D.M. Eccles1
1Cancer Sciences Academic Unit and Clinical Trials Unit, Faculty of Medicine, University of Southampton, Southampton, UK, 2Centre for Statistics in Medicine, Oxford, Oxford, UK

The DietCompLyf study: A prospective cohort study of breast cancer survival and phytoestrogen consumption

Year:

Session type:

Ruth Swann1, Annie Perkins1, Louiza Velentzis2, Cristian Ciria3, Susan Dutton3, Angela Mulligan4, Jayne Woodside5, Marie Cantwell5, Anthony Leathem6, Claire Robertson1, Miriam Dwek1
1University of Westminster, London, UK, 2Cancer Council New South Wales, Sydney, Australia, 3University of Oxford, Oxford, UK, 4University of Cambridge, Cambridge, UK, 5Queen’s University Belfast, Belfast, UK, 6University College London, London, UK

The effect of repeated invitations to prevalence screening on inequalities in the NHS Bowel Cancer Screening Programme

Year:

Session type:

Siu Hing Lo1, Christian von Wagner1, Julia Snowball2, Stephen Halloran2,3, Jane Wardle1
1University College London, London, UK, 2Bowel Cancer Screening Programme, Southern Hub, Royal Surrey County Hospital, Surrey, UK, 3University of Surrey, Surrey, UK

Current attitudes of head and neck oncologists in the United Kingdom to induction chemotherapy for locally advanced head and neck cancer: A survey of centres participating in a national randomised controlled trial

Year:

Session type:

Dorothy M Gujral1, Deborah Piercy2, James P Morden2, Marie Emson2, Emma Hall2, Aisha B Miah1, Shree A Bhide1, Katie L Newbold1, Kevin J Harrington1,3, Chris M Nutting1,3
1Head and Neck Unit, Royal Marsden Hospital, London, UK, 2Clinical Trials and Statistics Unit, Institute of Cancer Research, London, UK, 3Division of Radiotherapy and Imaging, Institute of Cancer Research, London, UK

An audit assessing if head and neck multi-disciplinary teams (MDTs) in hospital Trusts across England offer Fanconi anaemia (FA) testing for patients under the age of 45 with head and neck squamous cell carcinoma (HNSCC)

Year:

Session type:

Zain Sheikh1,2, Shahid Iqbal2, Hannah Blanchford2, James Adams2, Charles Kelly2
1Newcastle University, Newcastle upon Tyne, UK, 2Newcastle upon Tyne Hospital Trust, Newcastle upon Tyne, UK

Development of a microfluidic device to assess procoagulant activity in ovarian cancer in response to treatment with chemotherapeutic agents

Year:

Session type:

Kathryn Date1, Yuehua Dou1, Marina Flynn2, Leigh Madden1, John Greenman1
1University of Hull, Hull, UK, 2Castle Hill Hospital, Hull, UK

Next-Generation Sequencing analysis for detecting Human Papillomavirus in oral verrucous lesions

Year:

Session type:

Manar Samman1, Henry Wood1, Monica Pentenero3, Alec High2, Pamela Rabbitts1
1Leeds Institute of Cancer Studies and Pathology, Section of Pre-Cancer Genomics, University of Leeds, Leeds, UK, 2Department of Histopathology, St. James’s University Hospital and Leeds Dental Institute, Leeds, UK, 3Department of Oncology, Oral Medicine and Oral Oncology Unit, University of Torino, Turin, Italy

Glycoproteomics identifies cadherin-5 as a novel serum biomarker of metastatic breast cancer

Year:

Session type:

Simon Fry1, John Sinclair2, John Timms2, Anthony Leathem2, Miriam Dwek1
1University of Westminster, London, UK, 2University College London, London, UK

Agricultural land usage and bone cancer: Is there a link? Small-area analyses of osteosarcoma and Ewing sarcoma diagnosed in 0-49 year olds in Great Britain, 1985-2009

Year:

Session type:

Karen Blakey1, Richard Feltbower2, Roger Parslow2, Peter James1, Charles Stiller3, Paul Norman4, David Garthwaite5, Jacqueline Hughes6, Craig Gerrand7, Richard McNally1
1Institute of Health and Society, Newcastle University, Newcastle upon Tyne, UK, 2Paediatric Epidemiology Group, University of Leeds, Leeds, UK, 3Childhood Cancer Research Group, Department of Paediatrics, University of Oxford, Oxford, UK, 4School of Geography, University of Leeds, Leeds, UK, 5Food and Environment Research Agency, York, UK, 6Science and Advice for Scottish Agriculture, Edinburgh, UK, (NICR) Northern Institute for Cancer Research

International Cancer Benchmarking Partnership (ICBP) Module 4: Root Causes of Diagnosis and Treatment Delay in Four Cancer Sites: Lessons Learnt from the Northern Ireland Pilot Study

Year:

Session type:

Jackie Boylan1, Anna Gavin1, Conan Donnelly1, Module 4 Working Group2
1Queen's University Belfast, Belfast, UK, 2ICBP Module 4 Working Group, Canada, Australia, UK, Norway, Denmark, Sweden, UK

Clinical utility of serum epigenetics in cutaneous melanoma

Year:

Session type:

Hexiao Wang1, Lynda Weir1, Bhavya Rao1, Rubeta Matin2, Angela McHugh1, Colin Fleming3, Alan Evans4, Irene Leigh1, Gareth Inman1, Catherine Harwood2, Tim Crook1, Charlotte Proby1
1Division of Cancer Research, Ninewells Hospital & Medical School, University of Dundee, Dundee, UK, 2Centre for Cutaneous Research, Barts and the London Queen Mary University of London, London, UK, 3Department of Dermatology, Ninewells Hospital, Dundee, UK, 4Department of Pathology, Ninewells Hospital, Dundee, UK

Association of prognostic biomarkers with survival, response and toxicity in ovarian cancer patients from a three phase pharmacoepigenomic study

Year:

Session type:

Charlotte Wilhelm-Benartzi1, Nahal Masrour1, Michelle Metcalf1, Naina Patel1, Sarah Paracha1, Wei Dai1, Stan Kaye2, James Flanagan1, Robert Brown1,3
1Imperial College London, London, UK, 2Section of Medicine, Institute for Cancer Research, Sutton, UK, 3Section of Molecular Pathology, Institute for Cancer Research, Sutton, UK

BI-015 a novel diagnostic and prognostic prostate cancer biomarker that buffers the translational burden of neoplastic transformation

Year:

Session type:

Hayley Whitaker1,2, Jonathan Kay1, Anne Warren3, Ian Mills11, Benjamin Thomas1, Fredrik Wiklund5, Amanda Seipel4, Dan Berney6, Lars Egevad4, Gabrielle Fisher7, Chris Foster8, Colin Cooper10, Peter Scardino9, Jack Cuzick7, Henrik Gronberg5, David Neal1
1Uro-Oncology Group, Cancer Research UK Cambridge Institute, Cambridge, UK, 2Biomarker Initiative, Cancer Research UK Cambridge Institute, Cambridge, UK, 3Department of Histopathology, Cambridge University Hospitals NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge, UK, 4Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden, 5Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden, 6The Orchid Tissue Laboratory, Centre for Molecular Oncology, Barts and The London School of Medicine and Dentistry, London, UK, 7Research UK Centre for Epidemiology, Mathematics and Statistics, Wolfson Institute of Preventive Medicine, St Bartholomew’s Medical School, Queen Mary, University of London, London, UK, 8Department of Cellular Pathology and Molecular Genetics, Liverpool University Hospital, Liverpool, UK, 9Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, USA, 10Institute of Cancer, The Royal Marsden Hospital, Sutton, UK, 11Centre for Molecular Medicine, Oslo, Norway

How do patients fare in the real world? – Clinical practice outcomes of patients treated with Pazopanib for metastatic renal cell cancer

Year:

Session type:

Victoria Galvis1, Shien Chow1, Dionne Lawrence1, Robert Hawkins1
1The Christie Hospital, Manchester, UK

Impact on a general hospital of the publication of National Institute for Health and Clinical Excellence (NICE) guidelines on diagnosis of epithelial ovarian cancer (EOC)  

Year:

Session type:

Abigail Ford1, Oliver Marshall1, S Michael Crawford1
1Airedale NHS Foundation Trust, Keighley, UK

Diagnostics challenges of gastrointestinal stromal tumours (GISTs) – tumours that mimic GISTS

Year:

Session type:

Nadeera De Silva1, Amy Kwan1, Daniel Holyoake1, Han Wong1, Ramesh Bulusu1
1Addenbrooke's Hospital, Cambridge, UK

Evaluation of the management of Hodgkin’s disease in Blida, Algeria

Year:

Session type:

Messaoud Ayad1, Kahina Rabahi1, Kada Boualga1
1Centre Anti-Cancer, Blida, Algeria

Involved field radiotherapy versus no further treatment in patients with clinical stages IA and IIA Hodgkin lymphoma (HL) and a negative PET scan after 3 cycles ABVD. Results of the UK NCRI RAPID trial

Year:

Session type:

John Radford1, Sally Barrington2, Nicholas Counsell3, Ruth Pettengell13, Peter Johnson4, Jennie Wimperis5, Stewart Coltart6, Dominic Culligan7, Andrew Lister8, Eric Bessell9, Anton Kruger10, Bilyana Popova3, Barry Hancock11, Peter Hoskin12, Tim Illidge1, Mike O'Doherty2
1The University of Manchester and The Christie NHS Foundation Trust, Manchester, UK, 2PET Imaging Centre, St Thomas' Hospital, London, UK, 3Cancer Research UK and UCL Cancer Trials Centre, London, UK, 4University of Southampton, Southampton, UK, 5Norfolk and Norwich University NHS Foundation Trust, Norwich, UK, 6Kent and Canterbury Hospital, Canterbury, UK, 7Aberdeen Royal Infirmary, Aberdeen, UK, 8Barts and the London School of Medicine, London, UK, 9Nottingham City Hospital, Nottingham, UK, 10Royal Cornwall Hospital, Truro, UK, 11University of Sheffield, Sheffield, UK, 12Mount Vernon Cancer Centre, Northwood, UK, 13St George's, University of London, London, UK

Evaluation of multiple drug resistance in acute leukemia by real time PCR (RT-PCR)

Year:

Session type:

Eman Mosad1, Rania M Bakry1, Eman Hassan1
1South Egypt Cancer Institute, Assiut, Egypt

DNA repair proteins XPF and MUS81 are predictive biomarkers for oxaliplatin-fluorouracil chemotherapy in patients with oesophageal cancer

Year:

Session type:

Thomas MacGregor1,2, Richard Gillies2, Natasha Sahgal3, Rebecca Carter1, Runjan Chetty4, Lai-Mun Wang4, Nicholas Maynard2, Peter McHugh5, Mark Middleton1, Ricky Sharma1
1Department of Oncology, Oxford NIHR Biomedical Research Centre, Churchill Hospital, Oxford, UK, 2Department of Upper GI Surgery, Churchill Hospital, OUH NHS Trust, Oxford, UK, 3Wellcome Trust Centre for Human Genetics, Oxford, UK, 4Oxford NIHR Biomedical Research Centre/Department of Cellular Pathology OUH NHS Trust, Oxford, UK, 5Department of Oncology, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK

Neoadjuvant chemotherapy and prognostic subgroups defined by survival benefit in patients with locoregionally advanced nasopharyngeal carcinoma

Year:

Session type:

Messaoud Ayad1, Kahina Rabahi1, Kada Boualga1
1Centre Anti-Cancer, Blida, Algeria